Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Medical Specialties
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| DXCM | DexCom, Inc. | 5.70% | 364.49 | 8.2% | $1010.73m | |
| ABT | Abbott Laboratories | 1.85% | 89.88 | 0.8% | $687.47m | |
| MDT | Medtronic Plc | 5.18% | 102.01 | 0.6% | $656.19m | |
| BDX | Becton, Dickinson & Co. | -0.68% | 241.89 | 1.0% | $647.52m | |
| DHR | Danaher Corp. | 2.61% | 173.19 | 0.7% | $645.19m | |
| TMO | Thermo Fisher Scientific, Inc. | 1.72% | 354.13 | 1.0% | $503.14m | |
| BSX | Boston Scientific Corp. | 3.77% | 38.83 | 1.0% | $437.50m | |
| ISRG | Intuitive Surgical, Inc. | 5.05% | 592.76 | 2.4% | $398.72m | |
| SYK | Stryker Corp. | 4.48% | 206.95 | 1.3% | $354.31m | |
| INO | Inovio Pharmaceuticals, Inc. | 0.42% | 11.93 | 6.3% | $337.96m | |
| ALGN | Align Technology, Inc. | 10.82% | 288.21 | 6.4% | $324.61m | |
| WST | West Pharmaceutical Services, Inc. | 0.16% | 205.72 | 1.6% | $293.42m | |
| BAX | Baxter International, Inc. | 0.60% | 89.16 | 1.8% | $247.08m | |
| ZBH | Zimmer Biomet Holdings, Inc. | 6.12% | 137.44 | 1.7% | $203.62m | |
| QDEL | Quidel Corp. | -2.07% | 153.64 | 7.7% | $202.30m |
Company Profile
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.